CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
突变负荷和抗 PD-1 疗效并非普遍与免疫细胞浸润或淋巴样激活相关
英文原题：Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
查看英文原题
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对27,810例接受抗PD-1/L1治疗的晚期癌症患者的分析显示，免疫基因特征或免疫细胞浸润在不同癌症类型中并不普遍与突变负荷或免疫治疗后的长期生存者相关。因此，肿瘤的免疫学分层对肿瘤的免疫原性或免疫治疗结局影响有限。
展开英文摘要原文
Analysis of 27,810 patients with advanced cancers treated with anti-PD-1/L1 therapies shows that immune gene signatures or immune cell infiltration is not universally associated with mutation burden or long-term survivors after immunotherapies across cancer entities. Thus, immunological stratification of tumors has limited bearing on the immunogenicity of tumors or immunotherapy outcomes.
论文信息
- 作者
- Hsiehchen D、Elliott A、Xiu J、Seeber A、El-Deiry W、Antonarakis ES、Graff SL、Hall MJ
- 单位
- Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: gbtwnow@gmail.com.United States
- 文献类型
- 读者来信
- 期刊
- Cancer cell2024 Dec 9
- 原文标识
- PubMed 39577419 · DOI 10.1016/j.ccell.2024.10.017